SCHEMBL13069099

SCHEMBL13069099

Cc1nnc(C)c(-c2ccccc2Cl)c1-c1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.50
RAB9A P51151 5/20 0.50
ALDH1A1 P00352 3/20 0.50
TSHR P16473 2/20 0.50
HSD17B10 Q99714 2/20 0.50
KDM4E B2RXH2 2/20 0.50
TP53 P04637 2/20 0.50
NFKB1 P19838 1/20 0.50
CASP3 P42574 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
HSD11B1 P28845 3/20 0.44
HPGD P15428 2/20 0.44
MAOB P27338 1/20 0.44
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
BRD4 O60885 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13165378 0.83 APEX1 (0.48) NPC1RAB9ATSHRHSD17B10KDM4E
SCHEMBL2348260 0.76 APEX1 (0.45) NPC1RAB9ATSHRHSD17B10KDM4E
SCHEMBL896634 0.76 NPC1 (0.40) NPC1RAB9AKDM4EMAOBCNR1
SCHEMBL13165374 0.76 NPC1 (0.44) NPC1RAB9AKDM4ECASP3SENP8
SCHEMBL2455752 0.74 MEN1 (0.44) NPC1RAB9AALDH1A1KDM4ETP53
SCHEMBL3311845 0.73 NPC1 (0.42) NPC1RAB9AKDM4ECASP3SENP8
SCHEMBL671819 0.72 CYP2A6 (0.71) NPC1RAB9AALDH1A1TSHRHSD17B10
SCHEMBL29453518 0.72 CYP2A6 (0.71) NPC1RAB9AALDH1A1TSHRHSD17B10
SCHEMBL68893 0.72 NPC1 (0.47) NPC1RAB9ATSHRHSD17B10TP53
SCHEMBL2348112 0.72 NPC1 (0.41) NPC1RAB9AKDM4ECASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1775290-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2010-11-17 EP disclosed
US-7795258-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-14 US disclosed
US-7795258-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-14 US disclosed
US-20080275050-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-11-06 US disclosed
US-20080275050-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-11-06 US disclosed
EP-1775290-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2007-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275050-A1 Pyridazine Compound and Use Thereof CYP4Z1, PNPO, PLPBP NPC1 1625/4885RAB9A 1132/4885ALDH1A1 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.